Biotech Releases White Paper on Alzheimer's Disease Candidate
Source: Streetwise Reports
August 1, 2018 (Investorideas.com Newswire) A company focused on treatment of neurodegenerative diseases has issued a white paper discussing its lead candidate.
ProMIS Neurosciences Inc. (PMN:TSX; ARFXF:OTCQB) has issued a white paper in association with its participation in the 2018 Alzheimer's Association International Conference (AAIC), according to a July 31 press release. The company made a poster presentation at the conference regarding its lead candidate, humanized PMN310, which it says "shows unrivaled selectivity for native toxic AβO derived from human AD brains, with no off-target binding to Aβ monomers or plaque."
At the AAIC, one area of focus was "the causative role of amyloid-beta oligomers (AβO) in the development and progression of Alzheimer's disease (AD) and the importance of neutralizing AβO toxicity represented a common theme across multiple oral presentations and posters," the company stated.
The ProMIS white paper, titled "State of the Art at AAIC 2018," addresses that theme, exploring the idea that "targeting toxic amyloid-beta oligomers offers renewed hope for treatment of Alzheimer's disease."
"We believe the oligomer selectivity of PMN310 supports a potential best in class product profile compared to other therapeutic antibodies currently showing promising results in clinical trials," ProMIS President and CEO Dr. Elliot Goldstein stated.
Humanized PMN310 "is on track to enter Phase 1 clinical testing in the second half of 2019 and will include biomarker assessment as an integral part of the study design," according to the company.
1) Tracy Salcedo compiled this article for Streetwise Reports LLC and provides services to Streetwise reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following company mentioned in this article is a billboard sponsor of Streetwise Reports: ProMIS Neurosciences. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article, until one week after the publication of the interview or article.
This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release on the Investorideas.com newswire http://www.investorideas.com/News-Upload/
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.